Equity Profile

DNTH

Dianthus Therapeutics, Inc.

Health CareBiotechnology$6.1B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Dianthus Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with serious diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

$-1.02

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

DNTH Q2-2026 Earnings Preview

Context

Company Snapshot

Dianthus Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with serious diseases. Operating in the health care sector, its work is crucial as it aims to address unmet medical needs, particularly in oncology and immunology.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-6.28%

Avg Stock Reaction

+2.74%

Last Quarter Recap

In Q1-2026, Dianthus reported an EPS of $-0.85, which was better than the expected $-1.17, resulting in a positive surprise. However, there was no reported revenue, leaving investors eager for updates on future sales.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Dianthus to report a loss of $1.02 per share this quarter, with no revenue anticipated. Investors are keen to see if the company can continue to improve its EPS performance.

Bull Case

If Dianthus can exceed EPS expectations and provide positive commentary on future product developments, it could signal strong potential for recovery and growth.

Bear Case

Conversely, if the company fails to meet EPS expectations or provides no clear path to revenue generation, it could lead to a negative reaction from investors.

Key Metrics to Watch

EPS

$-1.02

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

Revenue

$0M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Dianthus provide any guidance on future revenue generation or product pipeline?

Investors are looking for clarity on how the company plans to transition from research to revenue, which is critical for its valuation.

How does the company plan to address the ongoing losses and improve EPS?

Understanding the strategy for reducing losses will be vital for investor confidence and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Dianthus's potential for revenue generation from its pipeline, as recent developments could lead to earlier-than-expected product launches.

Supporting Evidence

The company has a history of surprising analysts with better-than-expected EPS, indicating potential for positive surprises.

The options market is pricing in a significant move, which could reflect investor sentiment that the company may exceed expectations.

Key Risk

If Dianthus provides a clear path to revenue generation, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Dianthus can turn its financial performance around and start generating revenue.

Bull Confirmed If

An EPS of better than $-1.02, indicating improved financial performance.

Bear Confirmed If

An EPS worse than $-1.02, suggesting continued financial struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±23.01%

Historical Avg

±5.2%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±23.0% while DNTH has averaged ±5.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

38.6%

Calls (5K)P/C Ratio: 0.19Puts (2K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Dianthus beats EPS expectations, history suggests a potential stock increase of around 4.47% on average following a miss.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further guidance.

Miss

If the company misses EPS expectations, history suggests a potential decline of around 4.47%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the product pipeline and expected timelines for revenue generation.
2Details on cost management strategies to improve EPS.
3Insights into partnerships or collaborations that could enhance market reach.
4Comments on market conditions and competitive landscape in the biotechnology sector.
5Management's outlook on future financial performance and growth opportunities.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Dianthus Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with serious diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

$-1.02

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

DNTH Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-6.28%

Avg Stock Reaction

+2.74%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Dianthus to report a loss of $1.02 per share this quarter, with no revenue anticipated. Investors are keen to see if the company can continue to improve its EPS performance.

Bull Case

If Dianthus can exceed EPS expectations and provide positive commentary on future product developments, it could signal strong potential for recovery and growth.

Bear Case

Conversely, if the company fails to meet EPS expectations or provides no clear path to revenue generation, it could lead to a negative reaction from investors.

Key Metrics to Watch

EPS

$-1.02

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

Revenue

$0M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Dianthus provide any guidance on future revenue generation or product pipeline?

Investors are looking for clarity on how the company plans to transition from research to revenue, which is critical for its valuation.

How does the company plan to address the ongoing losses and improve EPS?

Understanding the strategy for reducing losses will be vital for investor confidence and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Dianthus's potential for revenue generation from its pipeline, as recent developments could lead to earlier-than-expected product launches.

Supporting Evidence

The company has a history of surprising analysts with better-than-expected EPS, indicating potential for positive surprises.

The options market is pricing in a significant move, which could reflect investor sentiment that the company may exceed expectations.

Key Risk

If Dianthus provides a clear path to revenue generation, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Dianthus can turn its financial performance around and start generating revenue.

Bull Confirmed If

An EPS of better than $-1.02, indicating improved financial performance.

Bear Confirmed If

An EPS worse than $-1.02, suggesting continued financial struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±23.01%

Historical Avg

±5.2%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±23.0% while DNTH has averaged ±5.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

38.6%

Calls (5K)P/C Ratio: 0.19Puts (2K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Dianthus beats EPS expectations, history suggests a potential stock increase of around 4.47% on average following a miss.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further guidance.

Miss

If the company misses EPS expectations, history suggests a potential decline of around 4.47%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the product pipeline and expected timelines for revenue generation.
2Details on cost management strategies to improve EPS.
3Insights into partnerships or collaborations that could enhance market reach.
4Comments on market conditions and competitive landscape in the biotechnology sector.
5Management's outlook on future financial performance and growth opportunities.